What Serina Therapeutics, Inc. does.

We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.

The therapeutic agents in our small molecule product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic (“PK”) profiles that can include toxicity, side effects and short half-life. We believe that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. We believe that POZ technology can be applied to small molecules, proteins, ADCs, and other classes of molecules.

Revenue and profit, by fiscal year.

More on SER.

• Serina Therapeutics, Inc. summary
• Serina Therapeutics, Inc. financial statements
• Serina Therapeutics, Inc. key metrics
• Serina Therapeutics, Inc. health scores and style box
• Serina Therapeutics, Inc. earnings
• Serina Therapeutics, Inc. dividends
• Serina Therapeutics, Inc. valuation
• Serina Therapeutics, Inc. ownership and insiders
• Serina Therapeutics, Inc. peers

Figures from Serina Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.